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Streptococcus pneumoniae DNA Initiates Type I Interferon Signaling
in the Respiratory Tract
Dane Parker,a Francis J. Martin,b Grace Soong,a Bryan S. Harfenist,a Jorge L. Aguilar,a Adam J. Ratner,a,c Katherine A. Fitzgerald,d
Christian Schindler,c and Alice Princea,b
Departments of Pediatrics,a Pharmacology,b and Microbiology and Immunology,c College of Physicians and Surgeons, Columbia University, New York, New York, USA,
and Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USAd
ABSTRACT Themucosal epithelium is the initial target for respiratory pathogens of all types. While type I interferon (IFN) signal-
ing is traditionally associated with antiviral immunity, we demonstrate that the extracellular bacterial pathogen Streptococcus
pneumoniae activates the type I IFN cascade in airway epithelial and dendritic cells. This response is dependent upon the pore-
forming toxin pneumolysin. Pneumococcal DNA activates IFN- expression through a DAI/STING/TBK1/IRF3 cascade.
Tlr4/,Myd88/, Trif/, andNod2/mutant mice had no impairment of type I IFN signaling. Induction of type I IFN sig-
naling contributes to the eradication of pneumococcal carriage, as IFN-/ receptor null mice had significantly increased nasal
colonization with S. pneumoniae compared with that of wild-type mice. These studies suggest that the type I IFN cascade is a
central component of the mucosal response to airway bacterial pathogens and is responsive to bacterial pathogen-associated
molecular patterns that are capable of accessing intracellular receptors.
IMPORTANCE The bacterium Streptococcus pneumoniae is a leading cause of bacterial pneumonia, leading to upwards of one mil-
lion deaths a year worldwide and significant economic burden. Although it is known that antibody is critical for efficient phago-
cytosis, it is not known how this pathogen is sensed by the mucosal epithelium.We demonstrate that this extracellular pathogen
activates mucosal signaling typically activated by viral pathogens via the pneumolysin pore to activate intracellular receptors
and the type I interferon (IFN) cascade. Mice lacking the receptor to type I IFNs have a reduced ability to clear S. pneumoniae,
suggesting that the type I IFN cascade is central to the mucosal clearance of this important pathogen.
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The airway epithelium is a primary site for the recognition ofboth viral and bacterial pathogens and initiates the host
defense against respiratory pathogens. Epithelial cells produce
chemokines and cytokines, such as interleukin-8 (IL-8), IL-6,
IL-1, granulocyte-macrophage colony-stimulating factor
(GM-CSF), and G-CSF, that function to recruit and activate
phagocytic cells to eradicate organisms and infected cells (1).
These mucosal epithelial cells are also a major source of the
type I interferons (alpha interferon [IFN-] and IFN-) that
are critical for viral clearance and coordinating immune regu-
lation (2). The role of type I IFNs in pulmonary defenses is
exemplified by the increased susceptibility of mice lacking the
IFN-/ receptor to influenza virus infection and secondary
bacterial pneumonia (3). Bacterial induction of type I IFNs has
been examined primarily within the context of infection due to
intracellular pathogens and limited to pathways expressed in
macrophages and dendritic cells (DCs) (4). These studies
indicate that the release of bacterial pathogen-associated mo-
lecular patterns (PAMPs) within the phagolysosome, from the
phagolysosome into the cytosol (5), or from bacteria within the
cytosol also induces type I IFN responses, a situation which
closely mimics viral infection (6). However, there is little data
to indicate how nonphagocytic cells could produce type I IFNs
in response to extracellular bacteria, such as the organisms
which most commonly cause pneumonia.
The upper airway is the initial site of colonization by
S. pneumoniae. Aspiration of these organisms into the lower
airways induces a florid proinflammatory response ascribed to
the stimulation of Toll-like receptors (TLRs) on the surface of
airway and immune cells and activation of NF-B-dependent
signaling. S. pneumoniae produces a cholesterol-dependent,
pore-forming toxin, pneumolysin (Ply), which has inherent
proinflammatory activity (7) and is critical in pathogenesis
(8, 9). As autolysis and the release of cell fragments accompany
pneumococcal replication, the pneumolysin pore provides a
conduit for these PAMPs to gain access to the mucosal airway
cells (10). The presence of bacterial components, especially
DNA, within the cytosol is a potent stimulus for the type I
IFN cascade (11) that can be recognized by a number of re-
cently described receptors, including RIG-1-like helicases, DAI
(DNA-dependent activator of IFN regulatory factors), and sev-
eral others (6, 11–15). In the experiments described herein, we
demonstrate that pneumolysin and DNA are involved in the
activation of type I IFN signaling, a response which contributes
to pneumococcal clearance from the airway.
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RESULTS
S. pneumoniae induces expression of type I IFN genes in the
murine lung. To test the hypothesis that S. pneumoniae activates
type I IFN signaling, C57BL/6J mice were infected intranasally
with 2 107 CFU of S. pneumoniaeD39 for 24 h and induction of
Ifnb and other cytokine-encoding genes in lung tissue was
analyzed using quantitative reverse transcription (qRT)-PCR
(Fig. 1A). A 10-fold increase in Ifnb was observed in addition to
induction of the IFN--inducible genes Mx1, PKR, and LIF (16,
17). The chemokine KC (as a positive control) and the cytokine
IL-6 (also a type I gene product) were up-regulated by almost
1,000-fold. To document that these type I IFN-dependent genes
were induced through the expected JAK/STAT signaling cascade,
phosphorylation of the STAT1 (P-STAT1) and STAT3 (P-STAT3)
transcription factors in the infected mouse lung tissues was dem-
onstrated and compared to a lipopolysaccharide (LPS) control
(Fig. 1B).
Pneumolysin contributes to induction of type I IFN signal-
ing in vivo and in vitro. S. pneumoniae pneumolysin is reported to
interact with TLR4 (7, 18), which interacts with TRIF (TIR
domain-containing adapter inducing IFN-) to participate in the
induction of type I IFN signaling. Recent data (19) have suggested
that the immune response to pneumolysin does not involve TLR4.
Pneumolysin also functions as a pore that allows bacterial PAMPs
access to the epithelial cytosol and pathogen recognition receptors
(10).We assessed Ifnb production inmice 4 h following intranasal
infectionwith 107 CFU of wild-type (WT) S. pneumoniaeD39 or a
ply null mutant. There was 40-fold induction of Ifnb by the WT
S. pneumoniae strain under these conditions but only a 3-fold
induction in mice infected with the ply mutant (P  0.029)
(Fig. 2A). At this 4-h time point, LIF andMx1were expressed and
this expression was pneumolysin dependent. Significantly re-
duced levels of KC and IL-6 were also associated with exposure to
the plymutant (P 0.001).
Despite equal numbers of WT andmutant bacteria in the lung
at this 4-h time point (Fig. 2B), there were significant differences
in the immune cell populations. Pneumolysin expression was re-
quired for the recruitment of neutrophils, as the ply mutant and
the phosphate-buffered saline (PBS) control attracted similar pro-
portions of neutrophils into the lung (Fig. 2C). Infection with the
ply null mutant resulted in the retention of a significantly (P 
0.0002) larger percentage of CD11c cells (analogous to PBS
mice), representing macrophages and DCs, than did infection
with WT S. pneumoniae (Fig. 2D), which is consistent with the
idea that Ply is a major immunostimulant (7, 20, 21).
To assess epithelial cell involvement in the signaling of the type
I IFN response, we tested the induction of Ifnb in murine airway
epithelial cells in primary culture. Murine airway epithelial cells
stimulatedwith S. pneumoniae had 10-fold induction of Ifnb at 4 h
compared with the 2-fold induction stimulated by the ply null
mutant (Fig. 2E). Ifnb induction in epithelial cells was not inhib-
ited by cytochalasin D, indicating that endocytosis was unlikely to
be involved in this signaling (Fig. 2F).
Pneumolysin-dependent pore formation is involved in in-
duction of type I IFN signaling.The role of pore formation in the
stimulation of Ifnb was examined using a Ply W433F mutant, a
toxoid (PdB)-expressing strain in the S. pneumoniae P1121 back-
ground that has 0.1% of the WT hemolytic activity but is still
capable of binding and oligomerizing into cellular membranes
(22, 23). STAT1 phosphorylation in murine lungs exposed to the
S. pneumoniae toxoid-expressing strain was substantially less than
that induced by the P1121 parent strain (Fig. 2G). We used fluo-
rescent (Alexa Fluor 488 [AF488]-labeled) Ply to follow the distri-
bution of the toxin in polarized airway monolayers, which was
limited to the apical surfaces, consistent with a role as a pore
(Fig. 2H). Activation of Ifnb was not detected when purified re-
combinant Ply was applied to the cells (Fig. 2I), as a control for
signaling that p38 phosphorylationwas still detected (see Fig. S1 in
the supplementalmaterial). However, when Ply was applied in the
presence of a ply pneumococcal cell lysate, a significant increase
(P 0.045) in Ifnb induction was observed, but not with a toxoid
version of the protein (Fig. 2J and Fig. S2 in the supplemental
material shows that the toxoid has significantly reduce hemolytic
activity). These results suggest that pneumolysin pore activity is
involved in the delivery of a ligand that activates type I IFN signal-
ing.
Induction of Ifnb by S. pneumoniae is TLR4, MyD88, trif,
andNod2 independent.Wenext examinedwhich signaling path-
ways are involved in mediating pneumococcal activation of
IFN-. As it has been suggested that Ply functions as a TLR4 ago-
nist (7, 18, 24), we tested the participation of TLR4 and its adaptor
TRIF in mediating pneumococcal type I IFN signaling (Fig. 3).
C57BL/6J WT, Tlr4/, and Trif/mice were intranasally inoc-
ulated with either PBS or 107 CFU of S. pneumoniae, and induc-
tion of Ifnb and STAT1 phosphorylation was examined 24 h later.
FIG 1 S. pneumoniae activates the type I IFN response in vivo. Mice were
infected with 2  107 CFU of S. pneumoniae and analyzed 24 h later. (A)
qRT-PCR of type I IFN and inflammatory cytokine genes fromRNA extracted
from infectedmouse lungs. Graphs display means with standard deviations (n
 3). (B) Immunoblots of transcription factors P-STAT1 and P-STAT3 from
mouse lungs. -Actin was used as a loading control. Each lane represents an
individualmouse. Data are representative of two experiments. LPS from E. coli
(50 g per mouse) was used as a positive control.
Parker et al.
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Not only did all of themice express Ifnb, but the Tlr4/mice had
increased levels of P-STAT1 (Fig. 3A and B) and Ifnb production
(3-fold higher than those of theWT; Fig. 3B), which were not due
to increased bacterial numbers in the lung (data not shown), as
has been reported by others (25). Trif/ mice were also able to
phosphorylate STAT1, indicating that endosomal TLR3 and
TLR4, which use Trif/Tram adaptors, are not involved in the re-
sponse to S. pneumoniae.
Type I IFN signaling through the other endosomal TLRs
(TLR7, TLR8, and TLR9) that utilize the adapter MyD88 (7) was
also excluded. In response to S. pneumoniae,MyD88/ null mice
had increased activation of STAT1 and Ifnb induction compared
to that of WT mice (Fig. 3A and B), consistent with increased
levels of infection (26).
We next screened for involvement of the cytosolic receptor
Nod2 (nucleotide-binding oligomerization domain 2), which
senses peptidoglycan (27) and can be transported via the pneu-
molysin pore (10, 28). Although a link between Nod2 and type I
IFN production has been observed (29–31), Nod2/ mice still
responded to S. pneumoniae (Fig. 3A and B).
Pneumococcal DNA activates IFN- expression. During ac-
tive growth, pneumococci spontaneously lyse, releasing cellular
components, including DNA. S. pneumoniae produces an autoly-
sin (LytA, an amidase) required for autolysis and release of cell
wall components (9). Incubation of epithelial cells with a lytA
strain of S. pneumoniae did not activate type I IFN signaling
(Fig. 4B), indicating that the inducing ligand is liberated from
lysed cells. DNA is a potent activator of type I IFN signaling, and
Ply could permit bacterial DNA to enter the cytosol, where it
would interact with one or more of the several different types of
DNA sensors that induce type I IFN signaling (11). Pneumococcal
lysates incubated with DNase were found to stimulate signifi-
FIG 2 Pneumolysin is involved in the induction of type I IFN. C57BL/6J mice were infected with 2 107 CFU of S. pneumoniae (S. p.) intranasally and studied
at 4 h (A to D). (A) WT-infected lung data are shown in black, and ply mutant-infected lung data are shaded grey. *, P  0.05 (Student’s t test; n  8). Lung
homogenates were analyzed for bacterial counts (B), neutrophils (percentage of Ly6G Ly6C CD45 cells) (C), and CD11c cells (D) by FACS. Lines represent
median values. *, P 0.05 (WT versus plymutant; Mann-Whitney test; n 8, except for the PBS controls). (E) Murine nasal epithelial cells in primary culture
were stimulated for the times indicated with WT or plymutant S. pneumoniaeD39 in the presence or absence of cytochalasin D (CytoD) (F). DMSO, dimethyl
sulfoxide. *, P 0.05 (Student’s t test; n 3). (G)Mice were intranasally administered S. pneumoniae strains (P1121 background) expressingWT pneumolysin,
no pneumolysin, or a nonhemolytic toxoid variant and examined 4 h later. Lung homogenates were immunoblotted for P-STAT1. Each lane represents an
individual mouse. (H) AF488-labeled pneumolysin is visualized in murine nasal epithelial cells at 1 h poststimulation. Murine epithelial cells in primary culture
following stimulationwith S. pneumoniaeD39 or purified pneumolysin (Ply) (I) or with ply lysates with andwithout purified pneumolysin or PdB (J). *, P 0.05
compared to unstimulated cells (Student’s t test; n 3). RNAwas extracted and analyzed for levels of IFN- by qRT-PCR.All graphs displaymeanswith standard
deviations.
S. pneumoniae Induces Type I Interferons
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cantly less (P 0.046) Ifnb than control lysates (Fig. 4A), further
implicating pneumococcal DNA as the ligand. To further impli-
cate pneumolysin in enabling DNA entry into the epithelial cells,
we demonstrated increased amounts of pneumococcal DNA in
murine epithelial cells incubated with WT S. pneumoniae com-
pared to the plymutant (Fig. 4C). However, reconstitution of the
system in vitro, i.e., adding purified Ply and S. pneumoniaeDNA to
murine airway epithelial cells in primary culture, did not result in
Ifnb induction.
DAIparticipates in sensing of pneumococcalDNA.There are
numerous receptors that respond to foreign DNA but relatively
few that do not involve TLRs.DNA receptors that stimulate IFN-
expression are available within both endosomes and the cytosol
(11). DAI is a cytosolic double-stranded DNA sensor that re-
sponds to DNA from several sources (32), although it has been
shown to be dispensable for DNA detection in cells isolated from
DAInullmice (33). In response to S. pneumoniae in the lung, there
was a significant (15-fold, P  0.002) increase in DAI transcrip-
tion, consistent with its known induction by IFN- (32) and sug-
gestive of involvement in pneumococcal signaling (Fig. 5A).
We took advantage of macrophage cell lines and dendritic cells
in primary culture to evaluate the participation of the expected
components of the DAI cascade in response to pneumococcal
DNA. To confirm that pneumococcal DNA was a ligand in im-
mune cells, we incubated pneumococcal lysate treatedwithDNase
or RNase before stimulating dendritic cells (Fig. 5B).We observed
a significant (90%, P  0.007) decrease in Ifnb induction in the
DNase-treated lysate. No loss of induction was observed in the
RNase-treated sample. The requirement for DAI in recognizing
pneumococcal DNA was confirmed in DAI-deficient macro-
phages (Fig. 5C). A significant (50%, P 0.048) decrease in Ifnb
induction was observed in DAI-deficient cells compared to that in
WT controls. This was not specific to just pneumococcal genomic
DNA, as DNA from Pseudomonas aeruginosa and Staphylococcus
aureus also stimulated reduced IFN- signaling in the DAI null
background (bone marrow-derived DCs) (see Fig. S3 in the sup-
plemental material; Fig. S4 with controls). We also investigated
the role of the recently identified factor STING (stimulator of IFN
genes) (14), which is essential for the recognition of non-CpG
intracellular DNA species (Fig. 5C). Transfection of bone
marrow-derived macrophages with pneumococcal DNA resulted
in a complete absence of Ifnb induction in the STING/ cells (P
 0.0001).
To confirm that the expected distal components of the DNA-
sensing cascade were involved, we transfected pneumococcal
FIG 3 Induction of IFN- production by S. pneumoniae in mice with muta-
tions in TLR4, Nod2, and innate adapters. WT and Tlr4/, Trif/,
MyD88/, and Nod2/ mutant C57BL/6J mice were infected intranasally
with 107 CFU of S. pneumoniae and examined 24 h later. (A) Lung homoge-
nates were assayed for STAT1 phosphorylation. Each lane represents an indi-
vidual mouse. Shown are representative experiments. (B) Lung tissue was an-
alyzed for induction of IFN- by qRT-PCR (n 4, except forNod2/mutant
mice [n 6]).
FIG 4 S. pneumoniae DNA activates type I IFN production. (A) Murine nasal epithelial cells were stimulated for 4 h with pneumococcal lysate that had been
left untreated or treated with DNase. (B) Murine nasal epithelial cells were stimulated for 4 h with the WT or lytAmutant strain (n 3). IFN- induction was
assessed by qRT-PCR and is displayed as fold induction over that in PBS-only controls. (C)Murine nasal epithelial cells were stimulated for 4 h with theWT and
plymutant strains (n 3). DNAwas extracted from the epithelial cells, and levels of S. pneumoniae 16S rRNAweremeasured by qRT-PCR. Un, untreated lysate.
*, P 0.05 compared to WT or untreated samples (Student’s t test). All results shown are representative of at least two independent experiments.
Parker et al.
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DNA into macrophage cell lines cells lacking TANK-binding ki-
nase 1 (TBK1) (in a TNFR1null background since TBK1nullmice
are embryonic lethal [34, 35]) (Fig. 5D) and IFN regulatory factor
3 (IRF3) (Fig. 5E) transcription factors, both of which were re-
quired for Ifnb induction, results consistent with the involvement
of DAI in the sensing of cytosolic DNA (15).
Participation of RIG-1, which stimulates helicase activity in a
complex with MAVS, resulting in IFN- expression through
TBK1 and IRF3 (12, 13), was excluded (Fig. 5F), as was signaling
through IRF5 (Fig. 5G) and IRF7 (Fig. 5H).
The significance of DNA sensing in the context of live organ-
isms was also addressed. S. pneumoniae-induced Ifnb transcrip-
tion in bone marrow-derived cells from DAI/mice was50%
decreased (P  0.048) and that in cells isolated from STING/
mice was 40% decreased (P  0.0081) compared with that in
controls (Fig. 5I and J). Macrophage lines deficient in TBK1 and
IRF3 displayed an even greater reduction of Ifnb induction
(Fig. 5K and L), confirming the participation of the expected com-
ponents of DAI-mediated IFN- signaling.
Type I IFNsignaling contributes toS. pneumoniae clearance.
The physiological role of type I IFNs in the pathogenesis of pneu-
mococcal infection was then explored by comparing the coloniza-
tion of WT mice with that of Ifnar/mice. At 7 days postinocu-
lation of 129 SvEv mice infected intranasally with 107 CFU of
S. pneumoniae, Ifnar null mice had significantly higher bacterial
counts (7-fold increase, P 0.0102) in nasal lavage fluid thanWT
controls (Fig. 6A). There were increased numbers ofmonocytes in
the lungs of infected Ifnar/mice (Fig. 6B; 14% versus 9%, P
0.0051) and dendritic cell populations (Fig. 6C; 4% versus 1.6%, P
 0.0079) compared with the WT controls, consistent with the
known effects of type I IFN signaling on the mobilization of im-
mune cells to the lung (36). Neutrophil recruitment was equiva-
lent between WT and Ifnar/ mice (Fig. 6D). We did observe a
difference in neutrophils in Fig. 2C, but this was in cells taken at an
early time point from an intranasal infection, and pneumolysin
can activate cytokines other than type I IFNs (37, 38). We did not
observe a difference in bacterial numbers in the lung in this model
(data not shown), consistentwith other studies (39). Thus, despite
FIG 5 Pneumococcal DNA is sensed by the cytosolic DAI sensor. (A)Mice were infected with 107 CFU of S. pneumoniaeD39 (S.p), and lung tissue was analyzed
for induction of DAI 24 h later (n 4). (B) Bone marrow-derived cells were stimulated with enzymatically treated S. pneumoniae lysates and then analyzed for
Ifnb production by qRT-PCR (n 3). (C) Bone marrow-derived cells from DAI/ (n 6) and STING/ (n 6) mice were transfected with pneumococcal
DNA, and Ifnb inductionwas analyzed by qRT-PCR. Ifnb induction of pneumococcal DNA-stimulated knockout bonemarrow-derived cells and their respective
controls downstream of DAI (D and E) and other type I signaling components (F to H) (n 3). Bone marrow-derived DCs and macrophages fromDAI/ (I)
and STING/ (J) mice (n 6) and TBK1/ (K) and IRF3/ (L) mice (n 3) were stimulated with S. pneumoniae for 2 h, and Ifnb levels were quantitated
by qRT-PCR. Graphs display means plus standard deviations and are representative of two experiments (excluding STING data), and data are expressed as fold
induction compared to that of the control cell line stimulated with PBS alone. *, P 0.05 compared to unstimulated or WT samples (Student’s t test).
S. pneumoniae Induces Type I Interferons
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the ability to recruit phagocytic cells, in the absence of type I IFN
signaling, there was increased colonization with S. pneumoniae.
DISCUSSION
In this report, we demonstrate the participation of airway epithe-
lial cells in the initial recognition of an important bacterial patho-
gen, S. pneumoniae, in the respiratory tract. This immune re-
sponse is mediated by activation of the epithelial type I IFN
cascade by the intracellular accumulation of pneumococcal DNA.
As this pathway is readily activated by viral nucleic acids that ac-
cumulate in airway epithelial cells, it is not unexpected that bac-
terial nucleic acids could have a similar effect. The upper respira-
tory tract is continually exposed to commensal flora, but the
bacterial components, including DNA released from lysed organ-
isms, do not appear to activate mucosal signaling. S. pneumoniae,
a pathogen, is distinct from commensal flora by virtue of its ex-
pression of pneumolysin, the pore-forming toxin that enables li-
gands to gain access to the epithelial cytosol and initiate type I IFN
signaling. As the induction of proinflammatory responses in the
lung is so potentially deleterious to respiration, it seems logical
that mucosal signaling is activated only by PAMPs that are sensed
intracellularly, by organisms that have breached the barrier func-
tion of the airway mucosa. Our findings suggest that type I IFN
signaling may be a general host response to perceived cellular in-
vasion and does not discriminate among types of pathogens,
whether viral or bacterial, but instead responds to the nature of the
specific PAMPS within the cell.
In a model of nasopharyngeal colonization, the usual route of
pneumococcal infection, the type I IFN response analogous to that
induced by influenza virus contributed to bacterial clearance. Pro-
duction of pneumolysin seems to be critical in triggering immune
recognition of S. pneumoniae as a pathogen. The role of type I IFN
signaling in the host response to pneumococcal infection has been
previously reported by Weigent et al. (40), who demonstrated
increased susceptibility to infection inmice treatedwith anti-IFN-
/ antibodies. Mancuso et al. (41) similarly investigated the im-
portance of type I IFN signaling in S. pneumoniae sepsis andmen-
ingitismodels. The significance of nasopharyngeal colonization in
the initiation of host defenses against S. pneumoniae was recently
highlighted in a microarray study that identified the induction of
a number of type I IFN-related genes in murine nasal lymphoid
tissue early in the course of a 6-week colonization (42). Less clear
is how necessary type I IFN induction is in the context of active
pneumococcal pneumonia, as models of pneumonia using direct
tracheal inoculation of the organisms fail to demonstrate a notable
phenotype (39). However, as upper airway colonization precedes
the development of pneumonia, this is a critical stage in the patho-
genesis of systemic pneumococcal infection.
It is increasingly apparent that the mucosal epithelium of the
lung provides much more than a physical barrier to infection but
actively participates in sensing and initiating immune signaling in
response to inhaled pathogens, both viral and bacterial. This sig-
naling includes not only the proinflammatory cascades set off by
the apically exposed TLRs but also intracellular sensing systems.
For at least two important pulmonary pathogens, S. aureus and
S. pneumoniae, shed components that are either endocytosed
(S. aureus protein A [36]) or taken up via pore formation (pneu-
molysin) trigger IFN- production in both epithelial and immune
FIG 6 Type I IFN production contributes to pneumococcal clearance. WT and Ifnar/ mutant mice (129/SvEV background for both) were infected with
107 CFU of S. pneumoniae intranasally and examined 7 days later. Shown are bacterial counts recovered from nasal lavage fluid samples (A) and percentages of
monocytic cells (percentage of CD11bCD45 cells) (B), DCs (percentage of CD11bCD11cCD45 cells) (C), and neutrophils (percentage of Ly6G Ly6C
CD45 cells) (D) from lung homogenates analyzed by FACS. Each data point represents an individualmouse (n 12).Data are combined from two independent
experiments. Lines represent median values. *, P 0.05 compared to WT mice (Mann-Whitney test).
Parker et al.
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cells. The ability of these PAMPs fromGram-positive extracellular
bacteria to access intracellular receptors suggests a central role for
the type I IFN cascade in mucosal defenses against respiratory
pathogens of all types.
The expression of pneumolysin is critical in the activation of
type I IFN signaling by S. pneumoniae. Pneumolysin has been
shown previously to facilitate the introduction of peptidoglycan
into host cells, as well as induce host signaling from osmotic
changes (28, 43). DNA from lysed commensal flora in the upper
respiratory tract could potentially be immunostimulatory, if the
organisms were able to deliver it into mucosal cells. The data sug-
gest that pneumolysin facilitates entry of DNA via its pore forma-
tion. We observed the requirement for pneumococcal lysis and
release of pneumococcal DNA as an autolysin null strain was un-
able to induce type I IFN signaling.We could obviate this require-
ment artificially by transfection of DNA or exposing naturally
phagocytic DCs to cell lysates. This suggests that the ability to
access cytosolic receptors may also contribute significantly to vir-
ulence. However, the addition of purified pneumolysin and DNA
did not activate signaling (data not shown). The inability to arti-
ficially recapitulate the system in vitro indicates a missing compo-
nent, alternative ligand, or stoichiometric effects necessary to ac-
tivate signaling.
Several discrete receptors in both the cytosol and endosomes of
the cells that make up the respiratory mucosa participate in type I
IFN signaling. Our data suggest that DAI, whose role in immune
signaling has been debated (15, 33), may be important in the re-
sponse to pneumococcal DNA and other bacterial DNA. There
was a significant induction of DAI expression by S. pneumoniae
and a significant requirement for DAI to induce Ifnb in response
to pneumococcal DNA. In addition, the contribution of other
potential DNA sensors and signaling components (MAVS, RIG-I,
andTLRs)was specifically excluded (although therewas a trend to
reduced induction in the MAVS null background, suggesting a
limited role for RNA polymerase III [12, 13]). The expected
downstream components of this pathway, including the recently
identified STING (stimulator of IFN genes), TBK1, and IRF3 pro-
teins, were also shown to be involved in the induction of Ifnb in the
contexts of both DNA and the whole organism.
There is a growing literature detailing how bacterial pathogens
induce the type I IFN cascade inmacrophages (6, 30, 44–47). This
report provides a second example of how an extracellular patho-
gen can activate type I IFN signaling, an intracellular response
(36). We now show that epithelial cells similarly participate in the
induction of type I IFN signaling. Exactly how the epithelial cells,
which are not actively phagocytic, are stimulated to express IFN-
in response to other types of airway pathogens remains to be es-
tablished. However, based upon our observations with the pneu-
mococcus, it seems likely that a general induction of type I IFN
signaling in the lung, including the airway mucosal cells, is an
important consequence of both bacterial and viral infections of
the lung.
MATERIALS AND METHODS
Bacterial strains. S. pneumoniae strains D39 (48), D39 ply (49), 1725
(P1121, a derivative of P833, a human carriage isolate [50]), 1726 (P1121
ply [10]), 1727 (P1121 ply plyW433F, a PdB toxoid-expressing strain
[28]), and D39 lytA (51) were grown on Trypticase soy agar (supple-
mented with erythromycin for D39 ply) or broth supplemented with
200 U/ml catalase (Worthington). Plate cultures were grown at 37°C in
the presence of carbon dioxide (5%). Escherichia coli strain BL21AI (In-
vitrogen), P. aeruginosa PAO1, and S. aureusUSA300 were grown at 37°C
on LB. All chemicals were purchased from Sigma unless otherwise stated.
RNA analysis. RNA was isolated using the RNAqueous-4PCR kit
(Ambion) with DNase treatment. cDNA was made using the iScript Syn-
thesis Kit (Bio-Rad). qRT-PCR was performed using Power SYBR Green
PCR Master Mix in a StepOne Plus thermal cycler (Applied Biosystems).
Samples were normalized to -actin or glyceraldehyde 3-phosphate de-
hydrogenase levels (sense, 5= ACCACAGTCCATGCCATCAC 3=; anti-
sense, 5= TCCACCACCCTGTTGCTGTA 3=). 16S rRNA primers for
S. pneumoniae were 5= GCCTACATGAAGTCGGAATCG 3= (sense) and
5= TACAAGGCCCGGGAACGT 3= (antisense). Primers for mouse actin,
Ifnb, Mx1, PKR, LIF, KC, IL-6, and DAI have been described elsewhere
(32, 36, 52).
Protein purification and labeling. E. coli BL21AI carrying pET29a/
pneumolysin or pneumolysin W433F (37, 53) was grown to mid-
exponential phase and induced with 1 mM isopropyl--D-
thiogalactopyranoside (IPTG) and 0.2% arabinose for 3 h at 37°C. Cells
were lysed using Bugbuster (Novagen) and sonication in the presence of
the HALT protease cocktail (Pierce). His-tagged protein was purified
from clarified lysates with nickel-charged agarose resin using Poly-Prep
gravity flow columns (Bio-Rad). Eluted protein was also passed through
an endotoxin removal column (Detoxi-Gel columns; Thermo Scientific).
When required, protein was concentrated to 2 mg/ml using Amicon cen-
trifugation columns and labeled with AF488 according to the manufac-
turer’s instructions (AF448 labeling kit; Molecular Probes-Invitrogen).
Hemolytic activity of proteins was confirmed (see Fig. S2 in the supple-
mental material).
Confocal microscopy. AF488-labeled pneumolysin (25 g/ml) was
incubated with murine nasal epithelial cells in primary culture for 1 h.
Cells were washed three times in PBS and fixed in 4% paraformaldehyde
before being blocked in 5%normal goat serumwith 0.3%Triton X-100 to
permeabilize cells. Phalloidin conjugated to rhodamine was used to stain
actin. Imaging was performed on a Zeiss LSM 510 META scanning con-
focal microscope and analyzed using LSM Image Browser software (ver-
sion 4.2).
Cell culture. Mouse nasal epithelial cells grown polarized from septa
were isolated from the indicated strains of adult mice and grown as de-
scribed elsewhere (54). Cells were stimulated with 5  108 CFU/ml of
bacteria. Purified pneumolysinwas applied to cells at a final concentration
of 2 g/ml for 4 h. Experiments were performed with cytochalasin D at
20 M and included a 30-min preincubation of inhibitor before the or-
ganism was applied. Pneumococcal lysate experiments were performed
using 5 mg/ml of protein. S. pneumoniae lysates (1 mg/ml) were treated
with 100U/mlDNase (Ambion) or 25g/ml RNase (digestion verified by
gel electrophoresis) for 2 h at 37°C before heat inactivation at 70°C for
10 min. DCs and macrophages were generated from bone marrow iso-
lated from femurs and tibias (fromDAI and STING null mice). DCs were
cultured for 7 days in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS), streptomycin, penicillin, and 20 ng/ml of GM-CSF
(PeproTech). Macrophages were grown in Dulbecco’s modified Eagle’s
medium with 10% FBS, ciprofloxacin, and 20% L929 supernatant. Im-
mortalized macrophages (from TBK1, IRF3, IRF5, IRF7, and MAVS null
mice) were prepared as described previously (55) and stimulatedwith 4
107 CFU/ml S. pneumoniae. Cell transfections were carried out using bac-
terial genomicDNA at a final concentration of 2g/ml. DNAwas isolated
using the DNeasy kit (Qiagen), and transfections were performed for 6 h
using FuGENE according to the manufacturer’s instructions (Roche).
Mouse studies. Lung infections with S. pneumoniae were performed
using 6-week-old C57BL/6J mice. Nod2/ mice were obtained from
Jackson Laboratories (originally from Regeneron Pharmaceuticals). Mice
were anesthetized with 100 mg/kg ketamine and 5 mg/kg xylazine and
intranasally inoculated with 2 107 to 5 107 CFU of the organism. LPS
from E. coli (50g permouse) was used as a control. Colonization studies
were performed with Ifnar/ and WT 129/SvEV mice. Six- to 7-week-
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oldmice were inoculated with S. pneumoniaeD39without anesthesia. For
fluorescence-activated cell sorter (FACS) analysis, red blood cells were
lysed from lung homogenates. Cells were suspended in PBS with 2% FBS
and stained with combinations of phycoerythrin-labeled anti-CD45
(Caltag Laboratories), fluorescein isothiocyanate-labeled anti-Ly6G/
Ly6C (clone RB6-8C5; BD Biosciences-Pharmingen), PerCP-Cy5.5-
labeled anti-CD11b (M1/70; eBioscience), and allophycocyanin-labeled
anti-CD11c (N418; eBioscience) antibodies in the presence of 10% nor-
mal mouse serum and Fc block (2.4G2; BD Biosciences). Negative con-
trols were stained with relevant isotype-matched antibodies. Cells were
fixed with 1% paraformaldehyde and analyzed on a FACScalibur (Becton
Dickinson) using CellQuest software (version 3.3; BD). Cells were gated
on their side and forward scatter and CD45 expression. Data were ana-
lyzed using WinMDI (version 2.8; Joseph Trotter). All mouse infections
were performed under the guidelines of the Institutional Animal Care and
Use Committee of Columbia University.
Western blotting. Phosphorylation of STATs was detected using
P-STAT1 (Y701; Abcam) and P-STAT3 (Y705; Cell Signaling Technol-
ogy) and normalized to -actin (Sigma), while phosphorylation of p38
was detected using P-p38 (T180/Y182; Cell Signaling Technology) and
normalized to total p38 (Cell Signaling Technology). All immunoblot
assays were followed by secondary antibodies conjugated to horseradish
peroxidase (Santa Cruz Biotechnology Inc.). Samples from at least two
individual mice were typically analyzed on two separate occasions. Pro-
tein separation, transfer, and immunoblotting were performed as previ-
ously described (36).
Statistics. Significance of data that followed a normal distribution was
determined using a two-tailed Student t test, and for data that did not
follow a normal distribution, a nonparametric Mann-Whitney test was
used. Statistics were performed with GraphPad Prism software.
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